Swiss Primary Biliary Cholangitis Cohort Study
1 other identifier
observational
500
1 country
13
Brief Summary
Research project in which biological material is sampled and health-related medical data is collected. In addition, already existing health-related medical data are used for further research. Coded data are used.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2017
Longer than P75 for all trials
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 15, 2017
CompletedFirst Submitted
Initial submission to the registry
May 8, 2017
CompletedFirst Posted
Study publicly available on registry
May 10, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
August 17, 2025
August 1, 2025
13.9 years
May 8, 2017
August 13, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Disease course
Observing disease course
3 years
Disease features
Observing disease features in Swiss population and see if they are similar to other countries'
3 years
Response to treatment
Observing response to treatment
3 years
Overall survival
Observing overall survival
3 years
Transplantation-free survival rate
Observing transplantation-free survival rate
3 years
Eligibility Criteria
Patients diagnosed with Primary biliary cholangitis according to recognized criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases). Subjects with isolated anti-mitochondrial antibodies and/or isolated PBC-specific anti-nuclear antibodies are also included. Patients/subjects aged at least 18 years and living in Switzerland are included.
You may qualify if:
- diagnose of Primary biliary cholangitis (according to EASL Clinical Practice Guidelines: management of cholestatic liver diseases).
- Subjects with isolated anti-mitochondrial antibodies and/or isolated PBC-specific anti-nuclear antibodies are also included
- Patients/subjects aged at least 18 years and living in Switzerland are included
You may not qualify if:
- N/A
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (13)
Fondazione Epatocentro Ticino
Lugano, Canton Ticino, 6900, Switzerland
Gastroenterologie und Hepatologie, Clarunis - Universitäres Bauchzentrum Basel
Basel, 4031, Switzerland
Inselspital
Bern, 3010, Switzerland
Spital Bülach
Bülach, 8180, Switzerland
Kantonsspital Graubünden
Chur, 7000, Switzerland
Hôpitaux Universitaires de Genève, Service de Gastroentérologie & Hépatologie, Département des Spécialités
Geneva, 1205, Switzerland
CHUV: Centre hospitalier universitaire vaudois
Lausanne, 1005, Switzerland
Kantonsspital Baselland
Liestal, 4410, Switzerland
Luzerner Kantonsspital
Lucerne, 6000, Switzerland
EOC Ospedale Regionale di Lugano - Italiano
Lugano, 6900, Switzerland
Kantonsspital St.Gallen
Sankt Gallen, 9007, Switzerland
Kantonsspital Winterthur
Winterthur, 8400, Switzerland
Universitätsspital Zürich
Zurich, 8091, Switzerland
Biospecimen
1. Serum (BD Vacutainer® SST II Advance) 2. RNA (PAXgene™ Blood RNA tube- 762165)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 8, 2017
First Posted
May 10, 2017
Study Start
February 15, 2017
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Last Updated
August 17, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share